Daraprim Alternative

A specialty pharmaceuticals company announces plans to produce a toxoplasmosis drug containing the same active ingredient as the pill at the center of an ongoing drug-pricing controversy.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, SLASHME While Turing Pharmaceuticals CEO Martin Shkreli said his firm would lower the price of its toxoplasmosis drug Daraprim following a controversial price hike, he didn’t say by how much or when. But some patients may not have to wait much longer for a low-cost alternative to the $750-per-pill treatment. San Diego-based Imprimis Pharmaceuticals today (October 22) announced that it would make a compounded drug formulation containing Daraprim’s active ingredient, pyrimethamine, available for less than $1 per pill—close to what the treatment cost before Turing acquired rights to Daraprim from CorePharma. Physicians can prescribe such compounded drug formulations when commercially available drugs do not meet the needs of a given patient, in accordance with federal and state law, Imprimis explained.

“This is not the first time a sole supply generic drug—especially one that has been approved for use as long as Daraprim—has had its price increased suddenly and to a level that may make it unaffordable,” Imprimis CEO Mark Baum said in the statement. “While we respect Turing’s right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim, for patients, physicians, insurance companies and pharmacy benefit managers to consider.”

Hat tip: Ars Technica

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Tracy Vence

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide